Evidence map›Paper›PMID 39080766›Full record

ArticleJournal of translational medicine2024

Targeting tumor-infiltrating CCR8

Qian Chen, Meiying Shen, Min Yan, Xiaojian Han, Song Mu, Ya Li, Luo Li, Yingming Wang, Shenglong Li, Tingting Li and 5 more

Abstract read
In one paragraph

Article in Journal of translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Observational
  13. Review
  14. Immunotherapy in Head and Neck Cancer.Cancer treatment and research · 2025
    Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Qian ChenDepartment of Immunology, School of Basic Medical Sciences, Chongqing Medical University, Chongqing, 400010, China.
Meiying ShenChongqing Key Laboratory of Tumor Immune Regulation and Immune Intervention, Chongqing Medical University, Chongqing, 400010, China.
Min YanDepartment of Immunology, School of Basic Medical Sciences, Chongqing Medical University, Chongqing, 400010, China.
Xiaojian HanDepartment of Immunology, School of Basic Medical Sciences, Chongqing Medical University, Chongqing, 400010, China.
Song MuDepartment of Colorectal Surgery, The Affiliated Hospital of Guizhou Medical University, Guiyang, 550004, Guizhou, China.
Ya LiDepartment of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Luo LiChongqing Key Laboratory of Tumor Immune Regulation and Immune Intervention, Chongqing Medical University, Chongqing, 400010, China.
Yingming WangDepartment of Immunology, School of Basic Medical Sciences, Chongqing Medical University, Chongqing, 400010, China.
Shenglong LiSchool of Basic Medical Sciences, Chongqing Medical University, Chongqing, 400010, China.
Tingting LiDepartment of Immunology, School of Basic Medical Sciences, Chongqing Medical University, Chongqing, 400010, China.
Yingying WangDepartment of Immunology, School of Basic Medical Sciences, Chongqing Medical University, Chongqing, 400010, China.
Wang WangDepartment of Immunology, School of Basic Medical Sciences, Chongqing Medical University, Chongqing, 400010, China.
Zhengqiang WeiDepartment of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Chao HuDepartment of Immunology, School of Basic Medical Sciences, Chongqing Medical University, Chongqing, 400010, China. huchao1510602@cqmu.edu.cn.
Aishun JinDepartment of Immunology, School of Basic Medical Sciences, Chongqing Medical University, Chongqing, 400010, China. aishunjin@cqmu.edu.cn.ORCID 0000-0001-9746-4220

Funding

Postdoctoral Research Foundation of China 2019M663444Science and Technology Research Program of Chongqing Municipal Education Commission KJQN202300440
6 · The paper itself

Abstract

backgroundChemokine (C-C motif) receptor 8 (CCR8) is a chemokine receptor selectively expressed on tumor-infiltrating regulatory T cells (Tregs). Strong immunosuppression mediated by CCR8

methodsTo study the presence and functional involvement of CCR8

resultsHere, we showed that Tregs was predominantly presented in the tumors of CRC patients (13.4 ± 5.8, p < 0.0001) and the CRC subcutaneous murine model (35.0 ± 2.6, p < 0.0001). CCR8 was found to be preferentially expressed on these tumor-infiltrating Tregs (CRC patients: 63.6 ± 16.0, p < 0.0001; CRC murine model: 65.3 ± 9.5, p < 0.0001), which correlated with poor survival. We found that majority of the CCR8

conclusionsCollectively, these findings illustrate the importance of CCR8

Indexed as

CD8-Positive T-LymphocytesColorectal NeoplasmsLymphocytes, Tumor-InfiltratingReceptors, CCR8T-Lymphocytes, RegulatoryAgedAnimalsCD4-Positive T-LymphocytesCell Line, TumorFemaleHumansImmunityMaleMiceMice, Inbred BALB CMiddle AgedCCR8 protein, humanReceptors, CCR8Chemokine (C-C motif) receptor 8 (CCR8)Colorectal cancer (CRC)Regulatory T cell (Treg)

Identifiers

PMID39080766
PMCPMC11290082

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.